Fasting insulin: difference between revisions
Diff·revision 15 → 16·16:00, 23 May 2025
Difference between revision 15 and revision 16 of Fasting insulin. 7 lines changed; the page grew by 694 bytes.
| Revision 15 — 21:02, 2 May 2025 ResolutionRoo (talk) expand §Standardisation 3,216 bytes ±0 | Revision 16 — 16:00, 23 May 2025 CPeptidePaddy (talk) add the pre-analytical requirement: tube type and time to separation 3,910 bytes +694 | ||
|---|---|---|---|
| 32 | A HOMA-IR threshold quoted without the assay it was derived from is not a threshold. This is the practical reason the index is better used to track change within an individual on one assay than to classify against a published cut-off.{{r|matthews1985}} | 32 | A HOMA-IR threshold quoted without the assay it was derived from is not a threshold. This is the practical reason the index is better used to track change within an individual on one assay than to classify against a published cut-off.{{r|matthews1985}} |
| 33 | 33 | ||
| + | 34 | == Behaviour under treatment == | |
| + | 35 | Fasting insulin falls with weight loss and with improved insulin sensitivity by any means, and the fall is a consequence of reduced demand rather than of reduced secretory capacity.{{r|drucker2018}} | |
| + | 36 | ||
| + | 37 | Under incretin therapy the picture is mixed: secretion is amplified while the drug is present, and sensitivity improves with weight loss, so fasting insulin reflects both influences. Attributing a change to either alone is unsound.{{r|wallace2004}} | |
| + | 38 | ||
| 34 | == References == | 39 | == References == |
| 35 | {{reflist}} | 40 | {{reflist}} |
| 36 | <ref name="wallace2004">Wallace TM, Levy JC, Matthews DR. "Use and abuse of HOMA modeling." ''Diabetes Care'' 27(6):1487–1495 (2004). DOI:10.2337/diacare.27.6.1487. PMID 15161807.</ref> | 41 | <ref name="wallace2004">Wallace TM, Levy JC, Matthews DR. "Use and abuse of HOMA modeling." ''Diabetes Care'' 27(6):1487–1495 (2004). DOI:10.2337/diacare.27.6.1487. PMID 15161807.</ref> |
| 37 | <ref name="matthews1985">Matthews DR, Hosker JP, Rudenski AS, et al. "Homeostasis model assessment." ''Diabetologia'' 28(7):412–419 (1985). PMID 3899825.</ref> | 42 | <ref name="matthews1985">Matthews DR, Hosker JP, Rudenski AS, et al. "Homeostasis model assessment." ''Diabetologia'' 28(7):412–419 (1985). PMID 3899825.</ref> |
| + | 43 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | |
| 38 | 44 | ||
| 39 | == See also == | 45 | == See also == |
| ⋮ | ⋮ | ||
| 42 | * [[Insulin secretion]] | 48 | * [[Insulin secretion]] |
| 43 | * [[Beta cell function]] | 49 | * [[Beta cell function]] |
| + | 50 | * [[Baseline laboratory panel]] | |
| 44 | 51 | ||
| 45 | {{DEFAULTSORT:Fasting insulin}} | 52 | {{DEFAULTSORT:Fasting insulin}} |